Microtubules have several key roles that are important in cell proliferation, trafficking, signalling and migration in eukaryotic cells. For this reason several microtubulebinding agents have been developed with different purposes, including for use as pesticides, antiparasitics and anticancer agents. In mammalian cells microtubules are present both in interphase cells and in dividing cells. In dividing cells, microtubules that constitute the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors. This explains why compounds that alter microtubule function have proved to be highly active in patients with cancer. The vinca alkaloids, identified over 50 years ago 1 and the taxanes, first isolated almost 40 years ago 2, 3 are currently administered in a large range of indications, including solid tumours and haematological malignancies [4] [5] [6] . They are most often integrated in combination chemotherapy regimens, including in some curative regimens, for example, in patients with non-Hodgkin's lymphoma. Taxanes have become an essential component in the adjuvant therapy and advanced setting of patients with breast cancer and are also extensively used in patients with ovarian cancer, non-small cell lung cancer (NSCLC) and Kaposi's sarcoma 7, 8 .
A peculiarity of microtubule-binding agents compared to other classes of anticancer drugs is their extreme structural diversity and in many cases, their structural complexity (FIG. 1) . It should be noted that many agents were isolated from marine organisms or from botanicals, which are not cultivated and in which they are present in only minute amounts 9 . Many of the most active agents, such as taxanes, were difficult to develop in the clinic owing to the scarcity of their natural sources (Pacific yew bark in the case of paclitaxel). This problem was in some cases later solved by partial or total synthesis of the compounds of interest, although total synthesis has not proved to be the best option for some compounds, such as taxanes 10 . This problem is still prevalent today for many of the new microtubule-binding agents, which explains, at least in part, the slow clinical development of many of the newer agents [11] [12] [13] .
In the age of small-molecule targeted therapies and therapeutic monoclonal antibodies, it is noteworthy that extensive resources and scores of clinical trials are still being devoted to the identification and evaluation of microtubule-targeted agents, including taxanes, epothilones, vinca alkaloids, halichondrins, maytansinoids, colchicine-site binding agents and others. This is partly due to the extremely large untapped reservoir of potentially therapeutic natural compounds, which influence microtubule dynamics and also add to our growing understanding of the role of the microtubule cytoskeleton in cancer cells. After briefly reviewing the mechanisms of action of and resistance to anticancer microtubulebinding agents, we will focus on novel agents, in particular, those that have recently been approved for marketing or reached the stage of clinical trials. An increasingly important issue that will be discussed is that of toxicity, as many of these microtubule-binding agents cause considerable neurological toxicity.
Mechanisms of action
A large number of chemically diverse substances, generally originating from natural sources, bind to tubulin and/or microtubules (TABLE 1) , altering microtubule
Dynamic
The non-equilibrium behaviour of microtubules in cells. Microtubule dynamics are faster during mitosis than during interphase and are crucial to cell division, making mitotic cells highly susceptible to microtubule-targeted drugs. They are also important in cellular trafficking and for cell migration.
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Adjuvant therapy
A treatment that is administered to patients with minimal or no detectable sign of disease in order to prevent disease recurrence.
polymerization and dynamics in diverse ways. A reasonable hypothesis is that plants and animals evolved this vast number of compounds that mimic endogenous regulators of microtubule behaviour in order to avoid predation. All of these compounds are antimitotic agents that inhibit cell proliferation by binding to microtubules and suppressing microtubule dynamics during the particularly vulnerable mitotic stage of the cell cycle (FIG. 2) . To document the suppressive effects of these agents on microtubule dynamics, most studies have used time-lapse microscopy to analyse interphase microtubules in live cells 14 . Spindle microtubule dynamics are more difficult to analyse because of microtubule density but may be indirectly evaluated by the study of centromere dynamics 15, 16 . These studies confirmed that inhibition of spindle and interphase microtubule dynamics occurred at the same concentrations as those inducing mitotic arrest (BOX 1; see Supplementary information S1 (movie)).
Depolymerizing versus stabilizing agents. The microtubule-targeted antimitotic drugs are often classified into two main groups, the microtubule-destabilizing agents and the microtubule-stabilizing agents, according to their effects on microtubule polymer mass at high concentrations. The so-called destabilizing agents inhibit micro tubule polymerization when present at high concentrations and most of these agents bind in one of two domains to tubulin; either the vinca domain or the This figure shows the extreme chemical diversity, as well as the complexity, of many of these agents. The complex structure of certain natural compounds explains the difficulty encountered by chemists to perform total synthesis of these molecules.
colchicine domain (TABLE 1) . Vinca-site binders include the vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine and vinflunine), the cryptophycins and the dolastatins (eribulin, spongistatin, rhizoxin, maytansinoids and tasidotin). Colchicine-site binders include colchicine and its analogues, podophyllotoxin, combretastatins, CI-980, 2-methoxyoestradiol, phenylahistins (diketopiperazine), steganacins and curacins 17, 18 . Some of the destabilizing agents, including hemiasterlin, estramustine, noscapine, herbicides such as carbendazim, psycho active drugs such as phenytoin and food components such as sulphoraphane identified in cruciferous vegetables 19, 20 , bind to novel sites on tubulin. The microtubule-stabilizing agents enhance microtubule polymerization at high concentrations and include the taxanes, paclitaxel and docetaxel (Taxotere; Sanofi-Aventis), the epothilones, ixabepilone (Ixempra; bristol-Myers Squibb) and patupilone, discodermolide, eleutherobins, sarcodictyins, cyclostreptin, dictyostatin, laulimalide, rhazinilam, peloruside A, certain steroids and polyisoprenyl benzophenones. Most of the stabilizing agents bind to the same or to an overlapping taxoidbinding site on β-tubulin, which is located on the inside surface of the microtubule 21 . However, two of the agents, laulimalide and peloruside A, are not displaced by paclitaxel and for this reason are thought to bind to a novel site on tubulin 22, 23 . overall several hundred compounds have been reported to arrest mitosis by their effects on microtubules. In all cases that have been investigated, they do so most potently by suppressing microtubule dynamics 24, 25 .
Suppression of microtubule dynamics. both classes of drugs, those that increase and those that decrease microtubule polymerization at high concentrations, potently suppress microtubule dynamics at 10-fold to 100-fold lower concentrations. The sensitivity of microtubule dynamics to regulation means that both kinds of microtubule-regulating drugs can kinetically stabilize the microtubules without changing the microtubule polymer mass. At a basic mechanistic level, these two classes of drugs act similarly to block mitosis. Supporting this common mechanism of action is the finding that taxanes and vinca alkaloids or estramustine can be combined in clinical chemotherapy regimens with no apparent antagonism [26] [27] [28] . In addition, combinations of taxanes with vinca alkaloids, estramustine or colchicine analogues have shown synergism in vitro 29, 30 . At high concentrations, there are clear differences in their cellular effects on microtubule mass 31 . However, to target cells as they enter mitosis in order to gain maximum therapeutic efficacy, it may be more important to maintain a low drug concentration in the tumour cells or in their adjacent endothelial cells for a reasonably long duration than to achieve a brief pulse of high intracellular drug concentration 32 .
Anti-angiogenic and vascular-disrupting effects.
The tumour vasculature is a superb therapeutic target as it is easily accessible to blood-borne drugs and tumour cells generally die unless they are continually supplied with oxygen and nutrients from the blood. The two approaches to inhibiting vascular function are to inhibit angiogenesis -the formation of new blood vessels -using antiangiogenic agents and to destroy the integrity of existing tumour vasculature using vascular-disrupting agents 33 . Formation of new blood vessels involves proliferation and migration of endothelial cells and both of these processes seem to be extraordinarily sensitive to microtubuletargeted drugs 25, 34 . It has been suggested that prolonged exposure times and frequent dosing of low concentrations of microtubule-targeted drugs, the so-called 'metronomic schedules' , may favour the anti-angiogenic properties of these agents. However, clinical confirmation of such an effect will require randomized trials and the expression of an anti-angiogenic effect in patients 32, 35 .
Since the late 1990s, the combretastatins and N-acetylcolchicinol-O-phosphate, compounds that resemble colchicine and bind in the colchicine domain of tubulin, have undergone extensive development as vascular-disrupting agents 36 . when combretastatin A4 phosphate is added to cultures of endothelial cells, microtubules rapidly depolymerize, cells become round within minutes, causing them to bleb and detach 37 . when administered to rodents, blood flow may drop by >95% in less than 1 hour, vascular permeability increases and haemorrhaging from peripheral tumour vessels occurs [38] [39] [40] . These vascular-disrupting agents seem to be fairly specific for tumour vasculature, although the reasons for this specificity are not known. As the targeted endothelial cells are non-tumour cells, a potential advantage of this approach is that the cells may be less susceptible to the development of resistance to these drugs than genetically unstable tumour cells. The development of these agents has also prompted new methods that aim to evaluate changes in tumour perfusion, such as dynamic magnetic resonance imaging measurements of gadolinium diethylenetriaminepentaacetate uptake and washout, positron emission tomography of 15 o-labelled water or dynamic contrast-enhanced magnetic resonance imaging [40] [41] [42] .
Several currently used microtubule-targeted agents, such as the vinca alkaloids, damage tumour vasculature in animal models. It is our belief that the difference between the classical antimitotic antiproliferative microtubule-targeted agents and the novel vascular-disrupting agents (agents that are undergoing clinical testing) may be due to the fact that the effects of vascular-disrupting agents are more rapidly reversible, either because of the reversibility of their binding to tubulin or because of their lack of long-term retention in cells. Consequently those agents that exert depolymerizing effects over a short period of time may act best as antivascular agents, whereas those that are retained and induce a long-term mitotic arrest may work best as antiproliferative agents.
Mechanisms of resistance
understanding the mechanisms of resistance to microtubule-binding agents is key in the development of novel, more potent microtubule-targeted compounds. resistance to microtubule-binding agents can occur at several stages in the pharmacodynamics of these agents, including primarily cellular efflux of the anticancer agents, ineffective interaction with the target and deficient induction of apoptosis. In addition, resistant tumours and cell lines show a multitude of changes in protein and microrNA expression and the relationship of these molecules to the actions of microtubules is not always easy to discern.
ATP binding cassette proteins and drug efflux. Membrane efflux pumps of the ATP binding cassette (AbC) family is the primary resistance mechanism developed by tumour cells exposed to microtubule-binding agents in vitro 43 .
Although P-glycoprotein (P-gp), the product of the MDR1 gene (also known as AbCb1) is responsible for the classical multidrug-resistant phenotype and actively effluxes vinca alkaloids and taxanes, thereby reducing their intracellular concentrations and cytotoxic activity, other transporters carry only some types of antitubulin agents. Vinca alkaloids are actively transported by the multidrug resistance-associated protein 1 (MrP1), taxanes are substrates for MrP2 and MrP7, and epothilone b is transported by MrP7 . Given the potential importance of these efflux pumps as mechanisms of resistance to chemotherapy, newer agents that are insensitive to active efflux have been identified and further developed (TABLE 1) . The clinical relevance of AbC pumps in patients with cancer remains controversial, with limited data to support the routine study of these proteins in patients 47 . Although the expression of these pumps in primary tumours often correlates with a lower response rate to therapy with microtubule-targeted agents, the presence Additional dimers are added head-to-tail and the resulting microtubules are highly dynamic structures containing a (+) end, characterized by an exposed β-tubulin peptide and a (-) end, characterized by an exposed α-tubulin peptide. b | Binding sites of microtubule inhibitors are shown (orange triangles, purple squares and yellow diamonds). Although vinca alkaloids, such as vinblastine, bind to microtubule ends, colchicine binds to soluble dimers, which can be incorporated in the microtubules. Taxanes, such as paclitaxel, bind along the interior surface of the microtubules. 
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Tubulin dimer
The heterodimeric protein subunit that polymerizes into microtubules. Each subunit is composed of one α-tubulin and one β-tubulin molecule.
Tubulin isotype
Tubulin peptides with slightly different amino acid sequences. The isotype varies between cell types in the same tissue and between tissues and also differs between tumour and non-tumour cells. The distribution of tubulin isotypes can be induced to change in response to drug treatment.
Rescue
The switch of a shortening microtubule end to growth or to a state of stable microtubule length.
Catastrophe
The switch of a growing or stable microtubule end to rapid shortening. and/or function of AbC proteins in clinical samples is not generally used to tailor therapy in individual patients due to difficulties in standardizing assays 48, 49 . Attempts to reverse drug resistance by combining microtubule agents with inhibitors of drug efflux proteins have been disappointing 50 . Conversely, the fact that microtubule-binding agents are substrates for AbC efflux pumps considerably limits their diffusion inside the central nervous system (CNS) and represents an obstacle to their oral administration, suggesting that new compounds, which are less susceptible to transport by AbC proteins, could possess new pharmacokinetic profiles 51 .
Alterations in microtubules.
A second level of resistance to antitubulin agents occurs through alterations in the target of these agents, the tubulin-microtubule complex. Qualitative or quantitative modifications of microtubules, which can influence drug binding or the effects of drug binding on tubulin conformation and/ or GTPase activity, are likely to influence sensitivity to microtubule-binding agents. These target-based mechanisms of resistance to microtubule-binding agents are extremely varied and are associated with either individual components of the microtubule array or regulatory proteins. Various proteins participate in tubulin protein folding, tubulin dimer sequestration, microtubule dynamics or interact with microtubules and tubulin and participate in their regulatory pathways. These include the proteins fragile histidine triad protein, microtubuleassociated protein 2 (MAP2), MAP4, stathmin, SToP (also known as MAP6) and survivin 24, [52] [53] [54] [55] [56] [57] . Alterations in the levels, intracellular localizations (nuclear or cytoplasmic), post-translational modifications and function of these proteins are likely to influence sensitivity to microtubule-binding agents.
Microtubules are composed of at least 13 isotypes of α-tubulin and β-tubulin. The quantitative tubulin isotype composition of microtubules can influence sensitivity to microtubule-binding agents. Most notably, increased levels of class III β-tubulin (βIII-tubulin) is associated with reduced response rates to taxanes in several tumours, including lung, breast and ovarian cancers 54, 58 . by contrast, epothilones may be indifferent to βIIItubulin content 59 . In addition to βIII-tubulin, increased levels of βV-tubulin and βII-tubulin have also been associated with taxane resistance [60] [61] [62] . by contrast, decreased expression of βIII-tubulin and increased levels of MAP4 protein have been detected in vinca-resistant cell lines, together with increased microtubule stability as identified by the high levels of polymerized tubulin 63 . However, small interfering rNA-mediated knockdown of either βII-tubulin or βIVb-tubulin sensitized lung cancer cell lines to vinca alkaloids 64 . It is worth noting that the role of βIII-tubulin expression in cancer may extend beyond its role in drug resistance. recent studies have discovered that βIII-tubulin seems to be a survival factor that can increase the incidence and the progression of cancer irrespective of the drug treatment 65 . These preclinical data have been confirmed in the clinic, in which high levels of βIII-tubulin are associated with worse prognosis and lower response rates in various tumour types 58, 66 .
Although there are several reports of mutations in tubulin genes occurring in cell lines resistant to microtubule-binding agents [67] [68] [69] , confirmation of these observations in the clinic is currently lacking. In spite of early suggestions that mutations in the taxol binding site were discovered in patients with NSCLC 70 , subsequent studies have shown no evidence that polymorphisms in β-tubulin genes are frequent events in clinical samples 71, 72 .
Box 1 | Microtubule dynamics
Microtubules are dynamic structures composed of α-tubulin and β-tubulin molecules that are constantly integrated or shed into the cytoplasm as the microtubules dramatically grow and shorten (see the figure) . Dynamics can be measured in live cells using fluorescently labelled tubulin (either labelled ex vitro and microinjected or labelled using an expressed green fluorescent protein tag) and video microscopy (see Supplementary information S1 (movie)). Several parameters of dynamics can be assessed to determine the effects of microtubule-targeted drugs on dynamics. These include the rates and the durations of growing and shortening events and the mean frequency of rescue or catastrophe. These parameters are generally analysed on interphase cytoplasmic microtubules and not on spindle microtubules. Systems using markers of the ends of spindle microtubules, such as green fluorescent protein-major centromere autoantigen B, have discovered that the suppressive effects of drugs on the dynamics of interphase microtubules are extremely similar to their suppressive effects on mitotic microtubules. The figure shows alterations in the length of individual microtubules in the presence of paclitaxel, highlighting the suppression of microtubule dynamic instability by this agent.
BCL-X L
B cell lymphoma extra large protein, an anti-apoptotic member of the BCL-2 family.
Superacid transformation
Chemical modifications induced by exposure to an extremely acidic environment.
Neutropaenia
Reduced granulocyte counts in blood, predisposing patients to infection.
Resistance owing to deficient apoptotic signalling. A third mechanism of resistance to microtubule-binding agents involves apoptotic signalling downstream of the microtubule-associated insults to which tumour cells are exposed. Microtubules physically interact with various cell organelles and various regulatory proteins (BOX 2) . An interesting case is that of the p53 tumour suppressor protein and its effect on sensitivity to paclitaxel. Hopes were raised by the observation that inactivation of p53 -a common mechanism of resistance to anticancer agents -induced preferential sensitivity to paclitaxel in normal human or murine fibroblasts 73 . However, later observations suggested that p53 status had little or no effect on sensitivity to taxanes 74, 75 . Several studies have failed to establish p53 as a predictive factor of response to taxanes in the clinic 76, 77 . Indeed, p53 may influence sensitivity to microtubule-binding agents by regulating microtubule composition and dynamics, thereby suggesting that p53 is not only a guardian of the genome but also a guardian of the microtubule cytoskeleton 57 . Apoptotic regulators or effectors also influence sensitivity to taxanes, for example a small molecule inhibitor of BCL-X L sensitized tumour cells to paclitaxel 78 .
It is also becoming clear that a balance in the expression of proteins that have no current recognized direct interactions with microtubules or tubulin can also modulate resistance or sensitivity to microtubule-targeted drugs. This possibly occurs through complex interactions with other proteins that are part of the recognized microtubule functions in transport, cell cycle, signalling and apoptosis. examples of these include prohibitin, glutathione S-transferase π, α-defensins, G2 and S phase-expressed protein 1 associated modulation of p21, and hypoxia and hypoxia-inducible factor 1α [79] [80] [81] [82] [83] . MicrorNAs also contribute to resistance to microtubule-targeted drugs. For example, the microrNA mir-125b conferred resistance to paclitaxel by suppressing the pro-apoptotic bAK1, whereas mir-148a increased sensitivity to paclitaxel by decreasing the expression of mitogen-activated and stress-activated protein kinase 1 (REFs 84, 85) .
Novel agents and/or formulations
Microtubule-binding agents are unique among anticancer agents not only because of their original mechanisms of action but also because of their extreme structural diversity. In most cases natural agents with potent antitumour activity have led the way for original synthetic analogues. Surprisingly this remains true even for the vinca and taxane families, the first members of which have been in clinical use for decades (TABLE 2) .
Vinca domain-binding agents. Vinca alkaloids (vincristine, vinblastine, vindesine and vinorelbine)
, originally isolated from the periwinkle plant Catharanthus rosea, is the oldest and to this day most diversified family (in terms of the number of approved compounds in a given family) of microtubule-targeted agents. Vinflunine, a novel fluorinated compound that was obtained by superacid transformation of vinorelbine in the presence of fluorhydric acid, has recently been approved for the second-line treatment of bladder cancer 86 . Also a liposomal formulation of the off-patent agent vincristine, which allows a prolonged and regular delivery of this active compound, is currently the object of clinical trials.
The dolastatin family, originally identified by the isolation of marine peptides from the ocean shell-less mollusc Dolabella auricularia, includes dolastatin 10, cemadotin, tasidotin (ILX651), soblidotin and malevamide e 87 . Although dolastatin 10 itself was not active in patients with various tumours, including advanced breast cancer or pancreaticobiliary cancers, its analogue soblidotin induced minor responses in patients with NSCLC and a partial response in a patient with advanced oesophageal cancer in a Phase I trial but was not further evaluated in a Phase II trial 88, 89 . romidepsin, a dolastatin 15 analogue, which also possesses activity as a histone deacetylase inhibitor, was recently discovered to be active in cutaneous T cell lymphoma with a 34% objective response rate 90 .
eribulin mesylate, a synthetic halichondrin derivative, was active in patients with metastatic breast cancer who relapsed after treatment with anthracyclines and taxanes. In a randomized Phase III trial patients receiving the single agent, eribulin mesylate, benefited from considerable improvement in overall survival when compared to patients treated according to the physician's choice of drug 91 .
Taxol domain-binding agents. besides paclitaxel and docetaxel, cabazitaxel (Jevtana; Sanofi-Aventis) displayed promising results in patients with breast cancer or prostate cancer and has recently been approved by the uS Food and Drug Administration for the treatment of metastatic hormone-resistant prostate cancer after the failure of docetaxel treatment 92, 93 . Issues with currently available taxanes include their mode of administration, currently limited to the intravenous route; their poor water solubility, requiring the use of surfactants such as polyethoxylated castor oil (Cremophor) and ethanol for intravenous administration, with an associated risk of hypersensitivity reactions 94, 95 ; and the nearly universal recurrence of disease when patients are treated in the advanced setting. Some of the new taxanes are poor substrates for AbC transport pumps and may in some cases be administered orally or pass through the blood-brain barrier, a particularly important property for the treatment of CNS metastases.
Conversely a Phase II trial evaluating bMS-275183, given orally twice weekly in patients with relapsing NSCLC, was terminated because of highly variable pharmacokinetics. unpredictable individual pharmacokinetics is a principal limitation in the development and use of orally administered anticancer agents.
Novel taxane formulations are being developed with the intent of reducing issues associated with poor solubility or hypersensitivity. In a Phase III trial comparing nano particle albumin-bound paclitaxel (Abraxane; Abraxis bioScience) and conventional docetaxel therapy in the treatment of patients with metastatic breast cancer, nanoparticle albumin-bound paclitaxel was associated with a better outcome as well as with a lower rate of severe neutropaenia and a similar rate of reversible sensory neuropathy 96 . Nanoparticle albumin-bound paclitaxel has
Corrected QT interval
The correlated QT interval is a heart rate corrected value that measures the time between the onset and the end of the heart's electrical cycle. A prolonged QT interval is a risk factor for ventricular tachyarrhythmias and sudden death.
Myelosuppression
Inhibition of bone marrow function, leading to reduced numbers of red blood cells (anaemia), white blood cells (leukopaenia) and platelets (thrombocytopaenia).
Kinetochore
The complex assemblage of proteins at the chromosome centromere to which dynamic mitotic spindle microtubules attach, ultimately producing equal segregation of chromosomes to the daughter cells. also shown activity in other settings including melanoma, gynaecological tumours and prostate cancer [97] [98] [99] . Several novel generic formulations of paclitaxel and docetaxel aim to eliminate surfactants from current formulations, which may eventually lead to reduced hypersensitivity reactions 100 .
epothilones were originally isolated from the myxobacterium Sorangium cellulosum. They are a promising novel family of agents for cancer treatment as they may retain activity against taxane-resistant tumours 101, 102 . epothilones are easier to produce than taxanes, display good water solubility and do not seem to be substrates for the P-gp efflux pump 103 , allowing passage through the blood-brain barrier 104 . besides ixabepilone (Ixempra; bristol-Myers Squibb), a semisynthetic analogue of epothilone b, which is currently approved for the treatment of advanced taxane-resistant breast cancer in the united States, several other epothilones are currently being studied in clinical trials. These include patupilone 105 , sagopilone [106] [107] [108] and KoS-862 (also known as epothilone D) 109, 110 , which are being evaluated in various solid tumour types.
Colchicine domain-binding agents.
Combretastatins are an exciting family of microtubule-targeted agents as they are lead compounds of the vascular-targeting agents or the vascular-disrupting agents, compounds that produce rapid disruption of tumour blood flow, probably by their effects on the microtubule cytoskeleton of endothelial cells. In Phase I trials combretastatin A4, isolated from the Combretum caffrum tree, induced unusual toxicities such as tumour pain, ataxia and cardiovascular modifications, including prolonged corrected QT interval and electrocardiogram modifications consistent with acute coronary syndrome [111] [112] [113] . Fosbretabulin is currently being evaluated in combination trials in patients with anaplastic thyroid cancer and with chemotherapy naive lung cancer 114 . other antivascular agents that have undergone clinical evaluation include ZD6126 (REF. 115 ), oXI4503 (REF. 116 ), ombrabulin (AVe8062A) 117 and crinobulin (ePC2407) 118 , as well as auristatin Pe (also known as TZT-1027, a dolastatin derivative) 119 , which binds in the vinca domain. A key issue for the regulatory approval of this family of agents will be the lack of major toxicity on normal vasculature, as well as the mode of administration in combination with other agents.
Additional agents binding at or near the colchicine binding-site of tubulin, such as CI-980 and 1069C85, have been discontinued, whereas AbT-751 (REF. 120) and indibulin are currently in Phase I trials (see Further information). Indeed, 2-methoxyoestradiol, displayed limited activity in patients with hormone-refractory prostate cancer 121 , breast cancer 122 and multiple myeloma 123 leading to improved formulations consisting of nanocrystal colloidal solutions 124 . The lack of myelosuppression by 2-methoxyoestradiol has been attributed to the resistance of the haematopoietic-specific β-tubulin to this agent 125 .
Other agents. Several other agents with novel properties have undergone clinical evaluation. Cevipabulin is an unusual agent that seems to bind to the vinca site but promotes microtubule polymerization 126 . Noscapine, which has the ability to cross the blood-brain barrier 127 is currently being evaluated in a Phase I/II trial in patients with multiple myeloma (ClinicalTrials.gov identifier: NCT00912899). Furthermore, several analogues of noscapine with increased potency in humans are under investigation as cancer therapeutics.
Toxicity of microtubule-targeted agents
The evaluation of some microtubule-binding agents has been discontinued because of significant toxicity. This is exemplified by the discodermolides, highly potent natural polyketide products isolated from the Caribbean sponge Discodermia dissolute, which seem to be synergistic with paclitaxel 128, 129 . A Phase I trial of this compound initiated in 2004 was interrupted because of significant pulmonary toxicity. Dictyostatin is a structurally related compound for which total synthesis has recently been obtained 130 . Cryptophycins, another class of agents associated with toxicity, were obtained from cyanobacteria or were prepared by total synthesis. Although some disease stabilization was observed in patients receiving cryptophycin 52 (also known as LY355703), there were no responses in patients treated for advanced NSCLC, in spite of significant neurological toxicity 131, 132 .
Neurological toxicity.
A chief limitation in the use of microtubule-targeted agents is the high rate of neuropathy induced by these compounds 133 . This potentially severe and dose-limiting side effect, which is dose-cumulative and more frequent in patients with pre-existing neuropathy -be it through chronic alcoholism or diabetes mellitus -usually manifests itself as a painful and debilitating peripheral axonal neuropathy for which there is currently no effective symptomatic treatment 134 . This has prompted the search for predictive factors, including neurological function tests or biological markers, such as myelin basic protein and gliofibrillar acid protein [135] [136] [137] . other manifestations include constipation or intestinal paralysis due to neurological toxicity against the autonomic nervous system. Although symptoms tend to disappear some months after the end of treatment, some patients retain considerable sequelae several years after therapy. The preferential toxicity of these agents for the nervous system is not understood at a mechanistic level.
Box 2 | Microtubule interactions with intracellular organelles
Microtubules interact with various intracellular components, including mitochondria, the Golgi apparatus, the endoplasmic reticulum and lysosomes. In the mitotic spindle microtubules allow the correct alignment of chromosomes during metaphase, followed by the equal distribution of chromatids to the two daughter cells during anaphase. This phenomenon relies on the physical interaction between the (+) ends of the microtubules and the kinetochores.
Several key proteins involved in the cell cycle and/or apoptosis also physically interact with microtubules. p53 is physically associated with dynein, a microtubule motor protein. BCL-2, survivin and several other proteins that have a role in cell survival also colocalize with microtubules. It is not clear if microtubules serve as molecular scaffolds for these proteins to exert their activity or if the proteins are sequestered by microtubules and therefore are functionally inactive.
However, it can be partially explained both by the relative abundance of tubulin in neurons and by the importance of an intact, functional microtubule cytoskeleton for adequate nerve conduction.
Peripheral neuropathy has been a limiting factor in the development of several agents, leading, as in the case of cryptophycins, to termination of their development. by contrast, there have been few reports of CNS toxicity with the currently administered agents, partly owing to the fact that they are P-gp efflux pump substrates and thus do not cross the blood-brain barrier. The development of newer agents, which are not substrates of P-gp, might be associated with CNS toxicity or with activity against tumours in the CNS 104 . The question of neuropathy is particularly important when considering the combination of these agents with other potentially neurotoxic agents. Among the classical agents, platinum compounds -which induce peripheral neurotoxicity to various degrees -are commonly used in combination with taxanes and vinca alkaloids, in particular in 
Milataxel
Phase II trials for mesothelioma Active in preclinical models of resistance to taxanes 203, 204 Larotaxel Phase III trials for pancreatic cancer Active in preclinical models of resistance to taxanes; poor multidrug resistance substrate [205] [206] [207] Ortataxel Phase II trials for taxane-resistant tumours Active in P-glycoprotein-expressing models 208 
Grade 4 neuropathy
Neurological toxicity induced by exposure to microtubulebinding agents, most often manifested as pain and numbness.
Iatrogenic leukaemia
Acute leukaemia caused by exposure to cancer chemotherapy; the prognosis is unfavourable.
patients with NSCLC or with germ cell tumours. In the case of patients with germ cell tumours a large number of long-term survivors were reported 138 . Among the more recently approved agents, several compounds, such as bortezomib and thalidomide, can also induce high grade peripheral neuropathy in a large proportion of patients. The mechanisms of neurotoxicity have not been precisely determined for all of these compounds and they may or may not be related to microtubules 139, 140 .
Combining these agents with microtubule-targeted agents may therefore prove to be difficult, and assays, which will quite probably be based on genetic polymorphisms, that predict high grade sensory neuropathy in individual patients would be of great use. A major difficulty in the screening of new agents is the lack of adequate preclinical models of drug-induced peripheral neuropathy. Glial cell cultures are extensively used to analyse this type of toxicity in vitro but animal models that reliably correlate with or predict neurotoxicity in patients remain imperfect [141] [142] [143] [144] [145] . The development of reliable predictive models would be of great use for the future development of novel agents and of neuroprotective compounds. Alternatively the identification of differences between the microtubule cytoskeleton in peripheral nerves and tumour cells could serve as a basis to design or select novel agents with reduced neuropathy. There are several agents that might not cause or cause only limited neurotoxic effects. eribulin induced no substantial reduction in nerve conduction velocity or amplitude in caudal and digital nerves when administered to mice at the maximal-tolerated dose 146 . Phase I and Phase II clinical trials of eribulin showed considerable activity with only a low incidence of neuropathy and no grade 4 neuropathy 147 . Indibulin has been reported to distinguish between mature neuronal tubulin and nonneuronal tubulin and has entered clinical evaluation as an oral formulation 148, 149 . In a Phase I study, ispinesib, a kinesin inhibitor was discovered to induce myelosuppression but no neurotoxicity 150 , although Phase II trials evaluating ispinesib as a single agent have not yet shown noteworthy activity 151, 152 .
Other toxicities. Myeloid toxicity is frequently observed with microtubule-targeted agents, with subtle differences between compounds in the same family 153 . Neutropaenia is often the most frequent and/or severe side effect observed in combination regimens that include these microtubule-targeted agents 70, 86, 154 . In several Phase II studies neutropaenia was one of the dose-limiting toxicities 88, [155] [156] [157] [158] . This toxicity, which is often added to similar toxicities of other agents used in combination regimens, is usually manageable. by contrast, some toxicities are relatively compound specific, such as fluid retention observed in patients receiving docetaxel or diarrhoea after patupilone therapy [159] [160] [161] .
An intriguing issue concerns the possible mutagenic properties of microtubule-binding agents and henceforth the risk that they may increase the risk of secondary tumours. Given the fact that cells exposed to these compounds can develop aneuploidy due to missegregation, there is a theoretical risk that these agents might increase the risk of iatrogenic leukaemias and/or solid tumours. Chromosomal instability and an aneuploid-prone phenotype have been described to be correlated with response to taxanes 162, 163 . Administration of paclitaxel to nude mice and to rhesus monkeys has caused prolonged aneugenicity and abnormal mitoses, respectively, but clinical confirmation of such an effect has yet to be shown 163, 164 . As these agents have been widely used in combination with alkylating agents and the initial indications mostly concerned patients whose life expectancy was short, it has been difficult to establish whether these agents are potentially carcinogenic per se. As a result of the widespread use of these agents in the adjuvant setting, in patients whose prognosis may be globally favourable, the question of whether microtubule-targeted agents increase the risk of secondary neoplasms has become clinically relevant.
Improving microtubule-targeted agents
Microtubules are a highly-validated target in cancer therapy, explaining the abundance of efforts to develop novel agents directed against this target. All of the currently approved compounds bind directly to tubulin, either to soluble tubulin or to tubulin that is polymerized into microtubules. However, the tubulin binding occurs at different sites on the tubulin molecule or to different regions of the microtubule. Novel approaches aim to improve on existing compounds by selecting agents that are insensitive to resistance mechanisms, that increase tumour selectivity, that reduce side effects such as peripheral neuropathy or that target the numerous other components of the tubulin-microtubule complex.
Several promising agents have been reported in preclinical models. These include eleutherobin 165 , laulimalide 166, 167 , hemiasterlins 168 , peloruside A 22,169 , taccalonolide 170 , coumarins 171 and cyclostreptin 172 . Most of the novel agents have been selected because of their activity in models that show resistance to taxanes. Several of these novel agents are not substrates of efflux pumps, such as P-gp or other AbC proteins. In some cases these agents are also insensitive to the presence of mutations in β-tubulin and/or to overexpression of specific tubulin isotypes, in particular βIII-tubulin, which has led some investigators to identify either βIII-indifferent agents or βIII-targeted agents 170, 173 . The exhibition that tumour aggressiveness and in some cases sensitivity to chemotherapy is influenced by the content of the βIIItubulin isotype suggests that the development of agents targeting this isotype would be of particular interest in patients with high-risk disease owing to the high expression of this isotype. Such a strategy is corroborated by the reports that inhibition of βIII-tubulin by oligonucleotides and by silencing rNA induced sensitization of tumour cells to various anticancer agents 62, 64 . In this regard, secotaxoids, which are predicted to bind well with high affininty to the βIII-tubulin isotype and retain activity in paclitaxel-resistant preclinical models seemed to be particularly promising but have not been further evaluated in the scope of recent clinical trials 174 . Another attractive approach involves vectorization of microtubule-binding agents to the tumour cell using a monoclonal antibody.
Maytansine conjugates are being studied in various indications, in particular in haematological diseases and in breast cancer [175] [176] [177] . In a trial of trastuzumab-DM1, a maytansinoid conjugated to the human epidermal growth factor receptor 2 (also known as erbb2)-specific therapeutic antibody trastuzumab, showed good efficacy in metastatic breast cancer and the CD56 targeting antibody-maytansine conjugate, lorvotuzumab-mertansine, has shown promising results in solid and liquid tumours that express CD56 (REFs 178, 179) .
It is now clear that alterations in microtubule dynamics are the main mechanism of action of microtubule-binding agents 24, 180 . Given the multiple roles of microtubules, several proteins other than tubulin itself are likely to constitute therapeutic targets in cancer cells. These potential targets include proteins involved in the life cycle of tubulin peptides and dimers, as well as proteins involved in microtubule nucleation, dynamics and interaction with chromosomes or cellular organelles. of particular interest are the motor proteins, such as kinesin eg5 (for which the first inhibitors, such as AZD4877, are currently being evaluated 181 ) and tau protein 182 , a key microtubule-associated protein, which has been correlated with positive outcome in patients with breast cancer. Another potential target is survivin 183 , a protein that is intimately involved in spindle microtubule behaviour as well as in apoptosis. other potential targets include mitotic centromere-associated kinesin, a protein that regulates microtubule dynamics 184 and stathmin 185 , an important regulator of the soluble tubulin dimer pool, as well as a regulator of tubulin dynamics.
Another important avenue for the optimization of microtubule-binding agents is the identification of patient subsets most susceptible to respond to therapy or to develop significant toxicity, using tumour-related parameters or patient characteristics 186 . This approach is of particular interest in diseases such as lung cancer, in which there are several therapeutic alternatives, none of which has clearly proved to be superior 187 . A randomized trial is currently analysing the potential benefit of ixabepilone in patients with βIII-tubulin-positive lung cancer (ClinicalTrials.gov identifier: NCT00723957). Analyses of targeted polymorphisms in patients receiving microtubule-binding agents has not yet allowed the identification of patients with the highest chance of response or the highest risk of developing dose-limiting side effects of chemotherapy 188 . High-throughput analyses of large patient cohorts and validation series will help establish personalized therapy with microtubule-binding agents.
Concluding thoughts
In light of the development of microtubule-targeted agents over the past decades, the recent approvals of a novel vinca alkaloid, a novel taxane and the first epothilone, in addition to the recent advances in understanding the role of the microtubule cytoskeleton in cancer cells, the stakes are high that this family of anticancer compounds will not only still be in use years from now, but will also will be considerably enriched with less toxic and highly active molecules. The tremendous diversity of naturally occurring compounds interacting with mammalian microtubules is a largely untapped source for future anticancer agents. A principal aim in this dynamic field will be to purify, screen and ultimately offer patients with cancer the best of nature's gems.
